drugset / Trial / NCT02578472

Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants

NCT02578472

Phase 1 Completed 36 enrolled Janssen-Cilag International NV
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of the study is to evaluate the effects of JNJ-42847922, compared to zolpidem and placebo, on driving performance as assessed by the mean difference of standard deviation of lateral position (SDLP) after forced awakening using a validated driving simulator test at 2, 4, 6 and 8 hours post-evening dose.

Timeline

Start
2015-11
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Seltorexant Small molecule 40 mg Oral
Subject Zolpidem Small molecule 10 mg Oral

Indications

No indication recorded.